GSK Announces Depemokimab Late-Breaking Data Presented At ERS Show A 54% Reduction In Severe Asthma Exacerbations; SWIFT-1 And SWIFT-2 Phase III Data Show Depemokimab Delivered Significant And Clinically Meaningful Reduction In Exacerbations Over 52...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.